The Oligonucleotides for Cardiovascular and Metabolic Disease Summit is dedicated to the biological and clinical challenges of cardiovascular and metabolic disease related to oligonucleotide drug development.
The Oligonucleotides for Cardiovascular and Metabolic Disease Summit covers topics such as:
- Designing successful clinical trials with appropriate dosage and administration strategies
- Viable targets in vascular, cardiac, and adipose tissue
- Next Generation Non-Coding Targets in Cardiometabolic Disease
- Validating Oligonucleotide Drug Target
- Dosing, Delivery, & Cellular Uptake Minimizing Off-Target Effect & Maximizing Oligonucleotide Delivery to Specific Tissues
- Translational Case Studies to De-risk & Optimize Clinical Trial Development
- Considerations for Rare & Broader Cardiometabolic Indications Balancing Efficacy with Ease-of-Use for Broader Popula
The Oligonucleotides for Cardiovascular and Metabolic Disease Summit brings together attendees from the pharma, biotech and health care industries.
